In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the ...
As the property security landscape evolves, Cloudastructure is strategically expanding its salesforce to address growing ...
As pulsed field ablation transformed the electrophysiology market over the last year, Boston Scientific Corp. emerged as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback